tofacitinib / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 70 Diseases   129 Trials   129 Trials   8945 News 


«12345678910111213...120121»
  • ||||||||||  tofacitinib / Generic mfg.
    UNRAVELING THE MECHANISMS UNDERLYING RESISTANCE TO JANUS KINASE INHIBITION IN ULCERATIVE COLITIS PATIENTS (A1) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_1996;    
    Our data underscores the pivotal role of macrophages in orchestrating responses to tofacitinib and strongly suggests that IL-10 blockade in these cells in the context of ongoing inflammation may explain the exacerbated disease in those patients who become refractory. Understanding the mechanisms underlying "drug escape" may aid in ensure efficacy, limit drug failure, and potentially guide follow-up therapeutic decisions.
  • ||||||||||  Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda
    PREDICTIVE BIOMARKERS OF THERAPEUTIC RESPONSE IN INFLAMMATORY BOWEL DISEASE: A STEP TOWARDS PERSONALIZED MEDICINE (A1) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_1993;    
    This study provides early insights into shifts in gene and protein expression in intestinal tissue, alterations in serum and urine metabolites, and changes in gut microbiota as potential predictors of response to biologics and JAK-inhibitor treatment. Further research is needed to validate these results and asses their clinical significance in identifying patients most likely to benefit from each therapeutic approach.
  • ||||||||||  Rinvoq (upadacitinib) / AbbVie
    ANTI-JAK EFFICACY IN A REAL WORLD COHORT OF ULCERATIVE COLITIS PATIENTS (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_1679;    
    In a cohort of multirefractory UC patients, JAKi demonstrated substantial efficacy in inducing clinical and endoscopic remission, though there was a decline in effectiveness during the maintenance phase. The rate of colectomy remained relatively low, underscoring the potential utility of JAKi in this challenging patient population.
  • ||||||||||  ADVANCED THERAPIES, THE BEST COMBINATIONS IN REFRACTORY IBD PATIENTS (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_1676;    
    The rate of colectomy remained relatively low, underscoring the potential utility of JAKi in this challenging patient population. DiseaseCombination of advanced therapy(number of patients)Partial or complete Clinical or biological responseAdverse effects, InfectionsUlcerative colitis (N=11)Vedolizumab / Tofacitinib (5)2/5 (40%)noneVedolizumab / Anti-TNFs (3)2/3 (50%)noneVedolizumab /Cyclosporin or Tacrolimus (2) Ustekinumab / Tacrolimus (1)1/2 (50%)1/1 (100%)noneCrohn
  • ||||||||||  Remicade (infliximab) / J&J
    SHORT AND LONG-TERM OUTCOMES AFTER ACUTE SEVERE ULCERATIVE COLITIS IN ADULTS: A 12 YEAR CANADIAN EXPERIENCE IN THE POST BIOLOGIC ERA (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_1638;    
    8% of patients admitted for ASUC require colectomy during the same admission and additional 13% required colectomy within 12 months of discharge. Despite a high initial response to corticosteroids, long term colectomy rates and re-hospitalization rates remain high.Table 1: Baseline characteristics and outcomes in adult patients with ASUC with comparison between steroid responders and non-respondersParameterOverall (n = 264)Steroid non-responders (n = 117) Steroid responders (n =147)P-valueExtent, n/N (%)ProctitisLeft sided colitisExtensive colitis9 (3.8)59 (24.9)169 (71.3)5 (4.9)26 (25.5)71 (69.6)4 (3.0)33 (24.4)98 (72.6)0.71Day 1Stool frequency (median [IQR])CRP (mg/L) (median [IQR])Albumin (g/L) (mean [SD])CRP/Albumin ratio (median [IQR])Seo index (mean [SD])Lindgren index (mean [SD])10.0 (7.0
  • ||||||||||  ADVANCED THERAPY IN PATIENTS WITH ULCERATIVE COLITIS AND MALIGNANT DISEASE: A CASE STUDY (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_1612;    
    Age, sex, disease duration, disease extent, severity, clinical course, intractable or not, use or not of azathioprine, type of AT, duration of AT, curability of malignant disease, type and duration of AT after onset of malignant disease, whether the onset of malignant disease was diagnosed during AT, duration of follow-up after onset of malignant disease, outcome of UC after onset of malignant disease, and outcome of malignant disease. ATOne drug: UST, ADA (2 patients)Two drugs: GLM?TOF (1 patient) Three drugs: IFX?UST?TOF?UST (1 patient)Five drugs: ADA?GLM?VED?TOF?UST (1 patient)Duration AT: range (median) (months)24
  • ||||||||||  TESTING MACHINE LEARNING WITH FINNISH REGISTER DATA TO PREDICT NON-RESPONSE TO CONVENTIONAL TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_1426;    
    Even though Finnish registries provide access to comprehensive longitudinal data allowing the generation of relatively large analysis cohorts, our ML model demonstrated a weak predictive potential, with low AUCs and accuracies (0.6 range), in line with previous findings.3 Due to scarcity of information on additional clinical variables available in the Finnish IBD registry, their use did not improve prediction of CT failure. Additional prediction difficulty is introduced by non-standardized data recording practices.
  • ||||||||||  Stelara (ustekinumab) / J&J
    THE ECONOMIC IMPACT OF USTEKINUMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A TARGETED LITERATURE REVIEW (Science Lounge) -  Jul 18, 2024 - Abstract #UEGW2024UEGW_748;    
    This literature review demonstrated that, despite its high efficacy, ustekinumab is among the highest costing biologics available for the treatment of IBD with low probabilities of cost-effectiveness across several studies. As the economic burden for IBD is increasing globally, cost-saving therapeutic options such as biosimilars may help to provide savings that can be redistributed in a healthcare system or provide funds to expand patient access.
  • ||||||||||  HS-10374 / Jiangsu Hansoh Pharma
    Enrollment open:  Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis (clinicaltrials.gov) -  Jul 18, 2024   
    P2,  N=160, Recruiting, 
    As the economic burden for IBD is increasing globally, cost-saving therapeutic options such as biosimilars may help to provide savings that can be redistributed in a healthcare system or provide funds to expand patient access. Not yet recruiting --> Recruiting
  • ||||||||||  tofacitinib / Generic mfg.
    Journal:  A novel approach with tofacitinib for the management of keratoderma blennorrhagicum in reactive arthritis: a case report. (Pubmed Central) -  Jul 17, 2024   
    Subsequent use of adalimumab and secukinumab resulted in worsening skin rash, prompting a switch to tofacitinib, leading to a remarkable improvement in pustular eruptions after 20 days of treatment. This case demonstrates successful application of tofacitinib in treating severe keratoderma blennorrhagicum refractory to conventional DMARDs and biologics, offering insights into JAK inhibition for challenging rheumatic diseases with skin involvement.
  • ||||||||||  tofacitinib / Generic mfg.
    Journal:  Tofacitinib Regulates Endostatin via Effects on CD147 and Cathepsin S. (Pubmed Central) -  Jul 13, 2024   
    Lastly, tofacitinib reduced endostatin' s degradation by inhibiting cathepsin S activity and recombinant cathepsin S reversed this in both systems. Thus, tofacitinib inhibits angiogenesis by reducing pro-angiogenic factors and enhancing the anti-angiogenic factor endostatin in a dual effect mediated partly through CD147 and partly through cathepsin S.
  • ||||||||||  Olumiant (baricitinib) / Eli Lilly, Rinvoq (upadacitinib) / AbbVie, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
    Journal:  Influence of Safety Warnings on the Prescribing Attitude of JAK Inhibitors for Rheumatoid Arthritis in Italy. (Pubmed Central) -  Jul 13, 2024   
    These data suggest that the warnings issued for TOFA were followed by a reduction in total JAKi prescriptions. However, the more selective JAKi (UPA and FILGO) were perceived by prescribers as favorable in terms of the risk/benefit ratio, and their use gradually increased at the expense of the other molecules.
  • ||||||||||  Olumiant (baricitinib) / Eli Lilly, Rinvoq (upadacitinib) / AbbVie, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
    Clinical, Retrospective data, Journal, Real-world evidence, Real-world:  Real-world comparative study of drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis. (Pubmed Central) -  Jul 11, 2024   
    Treatment with pan-JAKis and high baseline RA disease activity were identified as predictive factors for the discontinuation of JAKis. Lower drug retention rates were found in patients receiving pan-JAKis with high disease activity than in those without high disease activity.
  • ||||||||||  mercaptopurine / Generic mfg., tofacitinib / Generic mfg.
    Journal:  A case of IgG4-related disease associated with ulcerative colitis that was successfully treated with a JAK inhibitor. (Pubmed Central) -  Jul 8, 2024   
    Following the initiation of tofacitinib, a Janus-associated kinase inhibitor, it was possible to reduce the GC dose while maintaining remission of both diseases. This case highlights the potential utility of Janus-associated kinase inhibitors in managing complex cases of IgG4-related disease, especially those with concurrent conditions such as ulcerative colitis.
  • ||||||||||  tofacitinib / Generic mfg.
    Journal:  Tofacitinib for the Treatment of Trachyonychia. (Pubmed Central) -  Jul 8, 2024   
    This case highlights the potential utility of Janus-associated kinase inhibitors in managing complex cases of IgG4-related disease, especially those with concurrent conditions such as ulcerative colitis. No abstract available
  • ||||||||||  Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
    Enrollment change, Trial completion date, Trial termination:  Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib (clinicaltrials.gov) -  Jul 7, 2024   
    P4,  N=15, Terminated, 
    This study utilizing real-world data showed that upadacitinib was associated with improved disease-specific outcomes at 12 months compared to tofacitinib in patients with UC. N=100 --> 15 | Trial completion date: Dec 2024 --> Jul 2024 | Recruiting --> Terminated; Unable to recruit adequate numbers of participants to answer the research question.
  • ||||||||||  Vaxzevria (ChAdOx1-S recombinant) / University of Oxford, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, Spikevax (elasomeran) / Moderna
    Review, Journal:  Alopecia areata following COVID-19 vaccine: a systematic review. (Pubmed Central) -  Jul 6, 2024   
    N=100 --> 15 | Trial completion date: Dec 2024 --> Jul 2024 | Recruiting --> Terminated; Unable to recruit adequate numbers of participants to answer the research question. AA after COVID-19 vaccination is rare, and physicians should be aware of this phenomenon to improve early diagnosis and appropriate treatment.
  • ||||||||||  cyclophosphamide / Generic mfg., tofacitinib / Generic mfg.
    Journal:  An Unusual Case of Fever in Paralytic Ileus. (Pubmed Central) -  Jul 5, 2024   
    The patient received intravenous glucocorticoids and cyclophosphamide, resulting in a rapid clinical improvement. During the follow-up, tofacitinib was initiated based on the clinical response observed.